{"id":40659,"date":"2019-01-30T19:46:01","date_gmt":"2019-01-30T18:46:01","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=40659"},"modified":"2019-02-14T10:57:56","modified_gmt":"2019-02-14T09:57:56","slug":"aifa-istituisce-un-tavolo-permanente-per-i-pazienti-inerente-la-governance-farmaceutica","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-istituisce-un-tavolo-permanente-per-i-pazienti-inerente-la-governance-farmaceutica\/","title":{"rendered":"AIFA sets up a permanent table for patients regarding Pharmaceutical Governance. Monitor scientific information activities"},"content":{"rendered":"

In compliance with the guidelines of the Document on Pharmaceutical Governance<\/a>, the Italian Medicines Agency has decided to set up a permanent consultation table with patient associations within Open AIFA.<\/p>\n

\"\"<\/a>In the initiative that has always been dedicated to meetings with all the Agency's interlocutors, AIFA now intends to favor the active involvement of all citizens and patients by reserving an exclusive space for them.<\/p>\n

The Agency therefore invites patients, gathered in associations or even individual citizens with issues relating to the drug (e.g. access, research, safety), to contact it at the address openaifa@aifa.gov.it<\/a> and to consult the dedicated page<\/a> to view and sign the participation regulation.<\/p>\n

The opening of this channel of dialogue represents a valuable contribution to the regulatory activity, because it brings real experiences and skills that will improve the achievement of the primary objective which for AIFA is the promotion and protection of citizens' health.<\/p>\n

The agenda and reports will be made available on the Agency's institutional portal.<\/p>\n

We remind you that the channel remains open every day for individual patients, healthcare professionals and the general public Pharmalins<\/a>, to offer an independent and timely information service on contingent issues on authorized medicines.<\/p>\n

AIFA \u2013 30 January 2019<\/a><\/p>\n

Related news: Aifa. <\/strong>From the strengthening of pharmacovigilance to greater communication, transparency and speed in responses on therapeutic equivalence. Here is the 2019 activity programme<\/a><\/p>\n

AIFA. 2019 activity plan<\/a><\/p>\n

\n

AIFA. Four strategic guidelines and three major mission objectives accompanied by strategic objectives to be pursued. All with a view to ever greater transparency of information, but also ever more careful and punctual monitoring of the drug.<\/em><\/p>\n

…<\/em><\/p>\n

The third objective is the promotion of information and independent scientific research and to encourage investments in R&D in the pharmaceutical sector. <\/strong>In this context, the main strategic objectives are those of managing early access to medicines and promoting clinical research. But also the promotion of culture and independent information on medicines.<\/em>
\nFor the Minister it would be essential that Aifa prepares \u201can annual plan of activities in order to guarantee doctors independent information and to strengthen the role of the NHS. In line with the legislation, Aifa prepares an analysis of the scientific information activities on drugs carried out in Italy by pharmaceutical companies, in the field of both general medicine and hospital facilities".<\/strong><\/span><\/em><\/p>\n

Taken from dailyhealthcare.it<\/a><\/p>\n

AIFA programming 2019<\/a><\/p>\n

\"\"<\/a>
\n\u00a0<\/strong><\/span><\/p>\n

\u00a0<\/em><\/strong><\/p>","protected":false},"excerpt":{"rendered":"

In ottemperanza alle Linee guida del Documento in materia di Governance farmaceutica,\u00a0 l\u2019Agenzia Italiana del Farmaco ha deciso di istituire un tavolo permanente di consultazione con le associazioni dei pazienti all\u2019interno di Open AIFA. Nell\u2019iniziativa da sempre dedicata agli incontri con tutti gli interlocutori dell\u2019Agenzia, l\u2019AIFA intende adesso privilegiare il coinvolgimento attivo di tutti i …<\/p>","protected":false},"author":4,"featured_media":38089,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,79],"class_list":["post-40659","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-ssn"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=40659"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/38089"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=40659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=40659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=40659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}